Islatravir

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 414 publications

An optimized product-enhanced reverse transcriptase assay for sensitive and quantitative detection of HIV viral load and phenotypic drug resistance.

An optimized product-enhanced reverse transcriptase assay for sensitive and quantitative detection of HIV viral load and phenotypic drug resistance.

Journal: Journal of clinical microbiology
Published: August 31, 2026

Dose-ranging pharmacokinetics, safety, and efficacy of a 90-day intravaginal ring delivering islatravir in pigtail macaques.

Dose-ranging pharmacokinetics, safety, and efficacy of a 90-day intravaginal ring delivering islatravir in pigtail macaques.

Journal: Science advances
Published: August 26, 2026

Once-weekly oral islatravir plus lenacapavir: clinical considerations for individualized use.

Once-weekly oral islatravir plus lenacapavir: clinical considerations for individualized use.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: August 24, 2026

Doravirine/islatravir (Idvynso) for HIV.

Doravirine/islatravir (Idvynso) for HIV.

Journal: The Medical letter on drugs and therapeutics
Published: August 21, 2026

Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection.

Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection.

Journal: The Annals of pharmacotherapy
Published: August 11, 2026

Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.

Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.

Journal: JAMA
Published: July 31, 2026

Current evidence on islatravir drug resistance and implications for future HIV treatment.

Current evidence on islatravir drug resistance and implications for future HIV treatment.

Journal: Topics in antiviral medicine
Published: July 17, 2026

IDVYNSOTM (doravirine and islatravir).

IDVYNSOTM (doravirine and islatravir).

Journal: Clinical therapeutics
Published: July 15, 2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Journal: Lancet (London, England)
Published: July 07, 2026

Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.

Efficacy and safety of doravirine/islatravir for HIV-1: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.

Journal: HIV research & clinical practice
Published: July 04, 2026

Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review.

Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review.

Journal: Viruses
Published: June 25, 2026

Profile of People Living with HIV Switching Prior Antiretroviral Treatment to a Doravirine-Based Regimen in the Real-World Clinical Setting in Greece: The Retrospective DORAVITO Study.

Profile of People Living with HIV Switching Prior Antiretroviral Treatment to a Doravirine-Based Regimen in the Real-World Clinical Setting in Greece: The Retrospective DORAVITO Study.

Journal: Biomedicines
Published: June 24, 2026
Showing 1-12 of 414

Last Updated: 09/26/2026